Virologic Response Following a Switch to Dolutegravir-based Regimen in People Living with HIV/AIDS at a Tertiary Care Center in Nepal. Kathmandu Univ. Med. J. 2022;20(4):438-442. doi:10.3126/kumj.v20i4.54081